July 20, 2022

Opzelura can be used twice daily in patients ages 12 years and older The U.S. Food and Drug Administration has approved Opzelura (ruxolitinib) as the first topical treatment for vitiligo. The 1.5 percent cream is approved for continuous topical use twice daily to affected areas of up to 10 percent of body surface area in...